Bluejay Diagnostics Inc (BJDX) FinancialsBJDXBluejay Diagnostics Inc

Evaluating the bottom line, Bluejay Diagnostics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.89%, provide a clear picture of how effectively BJDX converts its operational activities into shareholder value.

In the context of the broader market, BJDX competes directly with industry leaders such as FEED and VTAK. With a market capitalization of $4.69M, it holds a leading position in the sector. When comparing efficiency, BJDX's gross margin of N/A stands against FEED's -111.30% and VTAK's 90.28%. Such benchmarking helps identify whether Bluejay Diagnostics Inc is trading at a premium or discount relative to its financial performance.

The financial performance of BJDX shows a consistent pattern of losses, with a net income loss of $2,324,013 in Q2 2026 and an EPS of -1.12. The company has a current ratio of 4.64, indicating good short-term liquidity, but the overall financial health is still concerning due to ongoing losses.